Delayed initiation of adjuvant chemotherapy among patients with breast cancer

JAMA Oncology

Volumn 2, Issue 3, 2016, Pages 322-329

  Chavez MacGregor, Mariana ^a   Clarke, Christina A ^b   Lichtensztajn, Daphne Y ^b   Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cancer Prevention Institute of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST NEOPLASMS; BREAST RECONSTRUCTION; CALIFORNIA; EPIDEMIOLOGY; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; REGISTER; TIME FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAMMAPLASTY; MIDDLE AGED; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84979503571     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3856     Document Type: Article

References (40)

1. American Cancer Society. Cancer Facts and Figures. http://www.cancer.org/acs/groups/content /@editorial/documents/document/acspc-044552 .pdf. 2015. Accessed September 30, 2015.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
3. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49(8):1996-2001.
4. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev. 1990;9(3): 171-174.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979; 63(11-12):1727-1733.
6. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39(10):3861-3865.
7. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol. 1994;102(4)(suppl 1):S3-S8.
8. Engel J, Eckel R, Kerr J, et al. The process of metastasisation for breast cancer. Eur J Cancer. 2003;39(12):1794-1806.
9. Department of Health and Human Services. Center for Medicare and Medicaid Services. 42 CFR Parts 405, 412, 413, 415, 422, 424, 485, and 488. http://www.gpo.gov/fdsys/pkg/FR-2014-08-22/pdf /2014-18545.pdf. Accessed February, 2015.
10. Biagi JJ, Raphael M, King WD, KongW, Booth CM, MackillopWJ. The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): A systematic review and meta-analysis. ASCO Meeting Abstracts. June 9, 2011 2011;29 (15-suppl):1128.
11. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, Gehan EA. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982;2(2): 163-169.
12. Cold S, DüringM, EwertzM, Knoop A, Møller S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93(6):627-632.
13. Colleoni M, BonettiM, Coates AS, et al; The International Breast Cancer Study Group. Early start of adjuvant chemotherapymay improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol. 2000;18(3):584-590.
14. Gagliato DdeM, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32(8):735-744.
15. Jara Sánchez C, Ruiz A, Martín M, et al. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat. 2007;101(2):215-223.
16. Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24(30):4888-4894.
17. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol. 2012;30(36):4493-4500.
18. Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003;21(20): 3792-3797.
19. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011;127(2):471-478.
20. Bauer KR, Brown M, Creech C, Schlang NC, Caggiano V. Data quality assessment of HER2 in the Sacramento region of the California Cancer Registry. J Registry Manag. 2007;34:4-7.
21. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593-602.
22. Yost K, Perkins C, Cohen R, Morris C,WrightW. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703-711.
23. Yang J, Schupp C, Harrati A, Clarke C, Keegan T, Gomez S. Developing an area-based socioeconomic measure from American Community Survey data. http://www.cpic.org/files/PDF/Research-Files/Reports/CPIC-ACS-SES-Index-Documentation-3-10-2014.pdf. 2014. Accessed September 30, 2015.
24. The National Institutes of Health National Cancer Institute. Find a Cancer Center. http://www .cancer.gov/research/nci-role/cancer-centers /find#California. 2015. Accessed October 1, 2015.
25. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23 (9):1934-1940.
26. Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2013;13:240.
27. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-1667.
28. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004;10(19):6622-6628.
29. FoulkesWD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-1948.
30. Hershman DL,Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99(3):313-321.
31. Bleicher RJ, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012;30(36): 4485-4492.
32. Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among womenwith breast cancer. MedOncol. 2013;30(1):419.
33. Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G, Lawrenson R. Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer. 2014;14:839.
34. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7): 1071-1082.
35. Fedewa SA, Edge SB, Stewart AK, HalpernMT, Marlow NM,Ward EM. Race and ethnicity are associated with delays in breast cancer treatment (2003-2006). J Health Care Poor Underserved. 2011;22(1):128-141.
36. Richards MA,Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353(9159):1119-1126.
37. Hershman DL, Tsui J,Wright JD, Coromilas EJ, TsaiWY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol. 2015;33(9):1053-1059.
38. Kimmick G, Anderson R, Camacho F, BhosleM, HwangW, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-incomewomen with breast cancer. J Clin Oncol. 2009;27(21):3445-3451.
39. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763-1768.
40. Colleoni M, Gelber RD. Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better? J Clin Oncol. 2014;32(8):717-719.